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Abstract  
Nitrite has emerged as an important bioactive molecule that can be biotransformed to nitric oxide 
(NO) related metabolites in normoxia and reduced to NO under hypoxic and acidic conditions to 
exert vasodilatory effects and confer a variety of other benefits to the cardiovascular system.  
Abundant research is currently underway to understand the mechanisms involved and define the 
role of nitrite in health and disease.  In this review we discuss the impact of nitrite and dietary 
nitrate on vascular function and the potential therapeutic role of nitrite in acute heart failure. 
Keywords: 
Nitrate; Nitrite; Nitric oxide; Vasodilatation; Heart failure.  
Abbreviations: 
AHF, acute heart failure; ALDH2, mitochondrial aldehyde dehydrogenase; BP, blood pressure; cGMP, 
cyclic guanosine monophosphate; CHF, congestive heart failure; CVD, cardiovascular disease; DBP, 
diastolic blood pressure; deoxyHb, deoxyhemoglobin; eNOS, endothelial nitric oxide synthase; FBF, 
forearm blood flow; FBF-R, forearm blood flow ratio; FMD, flow mediated dilatation; GTN, glyceryl 
trinitrate; Hb, hemoglobin; iNOS, inducible nitric oxide synthase; MAP, mean arterial pressure; Mb, 
myoglobin; NO, nitric oxide; nNOS, neuronal nitric oxide synthase; NOS, nitric oxide synthase; O2
-
, 
superoxide; ONOO
-
, peroxynitrite; oxyHb, oxyhemoglobin; RBC, red blood cell; ROS, reactive oxygen 
species; SAP, systemic arterial pressure; SBP, systolic blood pressure; sGC, soluble guanylate cyclase; 
UVA, ultra violet; XO, xanthine oxidase; XOR, xanthine oxidoreductase. 
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1. Introduction 
Cardiovascular disease (CVD) is the leading cause of death worldwide accounting for approximately 
30% of all global deaths (Global status report on non-communicable diseases 2010. Geneva, World 
Health Organization, 2011). The number of people who will die from CVD, mainly from heart disease 
and stroke, are projected to increase and reach approximately 23.3 million by 2030 (Mathers & 
Loncar, 2006).  Despite major advances in the treatment of patients with CVD, the morbidity and 
mortality associated with CVD is high, and there remains significant space for improvement in new 
therapeutic interventions.  With more potentially promising candidate therapeutics on the horizon, 
it is particularly important to test these new treatments in a clinical setting in order to improve the 
outcome for CVD patients through application of more effective therapies. 
The vascular endothelium is involved in many aspects of cardiovascular health, including regulating 
vascular tone, hemostasis, thrombosis, permeability and cell adhesion (Hirase & Node, 2012; Padilla, 
et al., 2013).  The endothelium releases vasodilatory substances including nitric oxide (NO), 
prostacyclin, C-type natriuretic peptide and endothelium-derived hyperpolarizing factor, as well as 
vasoconstrictors including endothelin-1, angiotensin II and thromboxane A2 (Danser, et al., 1994; 
Moncada & Vane, 1981; Needleman, et al., 1976; Vanhoutte & Katusic, 1988; Yanagisawa, et al., 
1988).  In the healthy endothelium, a balanced production of these factors plays an important 
preventative role against vascular disease. However endothelial dysfunction disturbs this balance 
and is associated with an increased risk of development of CVD, such as atherogenesis, increased 
arterial stiffness (arteriosclerosis) and associated hypertension. 
 
2.  Role of nitric oxide in vascular function  
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The discovery in the 1980’s that NO could be produced endogenously in the vasculature and exert 
vasodilatator effects led to a plethora of studies which demonstrated its pleotropic effects including 
control of blood pressure (BP) and vascular tone (Furchgott & Zawadski, 1980; Ignarro, 1999; 
Ignarro, et al., 1987; Loscalzo & Welch, 1995; Moncada, et al., 1988; Murad, et al., 1978).  NO is 
produced by a family of enzymes known as NO synthases (NOS) (Michel & Feron, 1997) utilizing the 
substrate L-arginine, molecular oxygen and nicotinamide adenine dinucleotide phosphate (Palmer, 
et al., 1988).  Three different isoforms of NOS have been identified.  Two of these are constitutively 
expressed in cells and synthesise NO in response to increased intracellular calcium concentrations 
(Mayer, et al., 1989; Moncada & Palmer, 1990; Mulsch, et al., 1989).  The constitutive enzymes are 
known as neuronal NOS (nNOS or NOS I) and endothelial NOS (eNOS or NOS III) (Michel & Feron, 
1997).  The third isoform, termed inducible NOS (iNOS or NOS II), is expressed in response to 
cytokines and other inflammatory factors in a variety of cells including macrophages, neutrophils, 
cardiac myocytes and endothelial cells (Szabo, et al., 1994) and produces NO independently of 
changes in intracellular calcium concentration.  More recently it has become clear, however, that the 
production of either constitutive NOS isoform can also be induced under certain conditions, and that 
some tissues express low levels of iNOS already constitutively.  Under normal physiological 
conditions low levels of NO produced by eNOS function as an important regulatory messenger and 
maintain vessel tone (Amezcua, et al., 1989; Loscalzo & Welch, 1995).  NO-induced vasodilatation is 
mediated by activation of soluble guanylate cyclase (sGC), which converts guanosine triphosphate 
into cyclic guanosine monophosphate (cGMP), and subsequently relaxes vascular smooth muscle 
(Ignarro, et al., 1981). 
When NO is produced at elevated levels, such as from iNOS during septic shock, NO can also have 
cytotoxic effects (Szabo, et al., 1993).  While lower levels of constitutively produced NO are involved 
in the regulation of mitochondrial activity by competing with oxygen at the level of complex IV of the 
respiratory chain (Erusalimsky & Moncada, 2007), higher concentrations of NO have been shown to 
persistently inhibit mitochondrial function by nitrosylation of electron chain complexes, in particular 
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complex I (Clementi, et al., 1998), and to cause DNA damage (Delaney, et al., 1993; deRojas-Walker, 
et al., 1995).  Endothelial dysfunction is apparent in conditions such as hypertension, heart failure, 
coronary artery disease, and atherosclerosis (Cai & Harrison, 2000; de Berrazueta, et al., 2010; 
Vanhoutte, 2009).  During these pathophysiological conditions, eNOS-dependent conversion of L-
arginine to NO is impaired and thus NO bioavailability is reduced, concurrent with decrease in NO-
mediated vasorelaxation (Harrison, 1997; Pou, et al., 1992; Shimokawa, et al., 1991; Wilcox, et al., 
1997).  Enhanced degradation of NO through scavenging by reactive oxygen species (ROS), together 
with a reduction in production via eNOS, has also been shown to be involved in reducing NO 
bioavailability (Harrison, 1997).   
NO scavenging by ROS (in particular superoxide, O2
-
) is normally controlled through a well-balanced 
production of NO and ROS, (Cai & Harrison, 2000).  However during pathological conditions when 
the production of NO decreases, the balance is perturbed (Griendling & Fitzgerald, 2003).  
Superoxide reacts with NO to form peroxynitrite (ONOO
-
) (Burney, et al., 1999).  Unlike NO, ONOO
-
 is 
a potent pro-oxidant which has been demonstrated to play a role in initiating lipid peroxidation in 
both membranes and lipoproteins (Radi, et al., 1991; Rubbo, et al., 1994; Thomas, et al., 1998).  
Consequently, ONOO
-
-modified low density lipoprotein has been shown to be involved in the 
accumulation of cholesteryl esters in the fatty streaks characteristic of atherosclerosis (Darley-
Usmar, et al., 1992; Guy, et al., 2001). 
Endothelial eNOS function may also become compromised as a result of increased oxidative stress. 
In atherosclerosis, for example, the flow of electrons from the reductase domain of eNOS to the 
oxidase domain (where L-arginine is oxidized) may become uncoupled from NO production. Under 
these conditions, the enzyme produces O2
- 
or ONOO
-
 in place of NO, a process referred to as “eNOS 
uncoupling”.  Uncoupling with a concomitant reduction in NO production occurs primarily when 
eNOS becomes monomeric (normally functional eNOS is a dimer) (Forstermann & Munzel, 2006; 
Zou, et al., 2004) and dissociation and/or oxidation of the eNOS cofactor tetrahydrobiopterin has 
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been suggested to play a key role in uncoupling (Bendall, et al., 2005).  Tetrahydrobiopterin 
availability is thought to be an important regulator in activity and uncoupling of eNOS (Bendall, et 
al., 2005).  A recent study in diabetes-induced mice suggests that tetrahydrobiopterin oxidation 
leads to eNOS uncoupling and dysfunction, with exogenous administration of tetrahydrobiopterin 
promoting eNOS dimerization and normalisation of eNOS function (Abudukadier, et al., 2013).    
Uncoupling of eNOS has been demonstrated in human arteries and veins concomitant with an 
increase in O2
-
 production (Margaritis, et al., 2013). Increases in O2
-
 production with consecutive 
endothelial dysfunction have been attributed to eNOS uncoupling (Vasquez-Vivar, et al., 1998), 
enhanced activity of NADPH oxidase (an enzyme whose primary function is to produce O2
-
) and 
xanthine oxidase (Jacobson, et al., 2007).   
Independent of oxidative stress and in addition to situations where the availability of the NOS 
substrate L-arginine may be compromised, a number of methylated arginine derivatives such as 
asymmetric dimethylarginine act as endogenous inhibitors of NOS and thus of NO generation (Böger, 
2003). Asymmetric dimethylarginine concentrations in plasma and tissues tend to increase in 
particular in patients with heart and renal failure, contributing to risk of adverse outcomes in such 
individuals (Visser, et al., 2010). 
Thus, endothelial dysfunction can be a result of several different abnormalities affecting either 
production or availability of NO, and under many pathophysiological conditions it is possibly a multi-
factorial process.  Therefore, in most cases no causative treatment option will be available. An 
attractive alternative to rescuing compromised endothelial function by correcting the true cause of 
the malfunction is administration of an alternative source of NO. Current treatment options for 
conditions such as angina, myocardial infarction, and heart failure include administration of organic 
nitrates, for example glyceryl trinitrate (GTN) as a source of NO, causing coronary vasodilatation 
(Marsh & Marsh, 2000).  However, undesirable side effects including a throbbing headache and 
orthostatic problems as well as tolerance development (limiting drug efficacy when administered for 
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a prolonged period of time) have led to an intense search for superior treatment options.  As judged 
by the outcome of several animal experimental studies, inorganic nitrite (NO2
-
) administration may 
hold promise for the treatment of conditions associated with endothelial dysfunction by improving 
vascular function following biotransformation to NO; if found to be of value in human trials as well, it 
may become an attractive treatment alternative to organic nitrates in the future.  
In this review, we discuss nitrite as a potential NO substitute, the mechanisms involved in nitrate 
bioactivity and the role of nitrite in cardiovascular health and function. 
 
3.  Nitrite as a potential nitric oxide substitute 
The nitrate-nitrite-NO pathway has been proposed as an alternative pathway for NO generation 
(Lundberg et al., 2008).  NO produced through this pathway has been proposed to represent a NOS-
independent alternative to the classical pathway in which NO is produced by oxidation of L-arginine 
in a reaction catalyzed by NOS (Lundberg et al., 2008). Under normal physiological pH and oxygen 
tension, nitrite is an endogenous substance produced via the oxidation of NO (in cells by cytochrome 
C oxidase (Torres et al, 2000), in blood principally by ceruloplasmin; Shiva et al., 2006), and for many 
years nitrite was simply considered a relatively inert metabolic end-product of NO.  However in the 
past decade, it has become apparent that under certain conditions nitrite exerts potent biological 
effects, and several research groups have identified that – particularly at low pH and oxygen tension 
- nitrite is reduced by various nitrite reductases to NO (Aamand, et al., 2009; Cosby, et al., 2003; 
Feelisch, et al., 2008; Rassaf, et al., 2007; Shiva, et al., 2007a; Totzeck, et al., 2012a; Webb, et al., 
2004; Webb, et al., 2008a).  Table 1 summarises various animal studies that have evaluated the 
efficacy of nitrite as a vasodilator and/or BP lowering agent.  In vivo, nitrite is readily oxidised to 
nitrate (NO3
-
) by cellular and acellular processes, and the latter can be reduced back to nitrite via 
mechanisms involving the commensal bacterial flora of the oral cavity and the gut as well as 
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reduction by xanthine oxidoreductase (XOR) in the host tissues (Lundberg, et al., 2009). This had led 
to the conceptualisation that a ‘nitrogen oxide cycle’ exists by which dietary sources of nitrite and 
nitrate mix in with nitrite and nitrate produced by the oxidation of endogenous NO, suggesting a 
common circulating pool contributes to bodily NO production.   
An important physiological role for the nitrate-nitrite-NO pathway is increasingly becoming apparent 
in the literature as its activity under various conditions is being uncovered.   It has been shown by a 
number of research groups that nitrite-derived bioactivity is cardioprotective by minimising cell 
death by apoptosis (Dezfulian, et al., 2007; Duranski, et al., 2005; Shiva, et al., 2007a; Shiva, et al., 
2007b; Tripatara, et al., 2007;  Webb, et al., 2004), exerts anti-aggregatory effects (Corti, et al., 2013; 
Park, et al., 2013; Srihirun, et al., 2012; Velmurugan, et al., 2013), inhibits hypoxic and inflammatory 
pulmonary arterial hypertension (Bueno, et al., 2013; Sparacino-Watkins, et al., 2012; Baliga, et al., 
2012), and that it increases forearm blood flow (FBF) and decreases BP by acting as a vasodilator 
(Cosby, et al., 2003; Dejam, et al., 2007; Maher, et al., 2008).  In addition, nitrate has been shown to 
improve exercise performance by reducing the oxygen cost of exercise in skeletal muscle (Larsen, et 
al., 2011).  Since this profile of action resembles that of NO (and the latter can be measured as a 
reaction product under specific reaction conditions) it is widely believed that NO is the active 
principle that underpins most if not all of the actions of nitrite (and nitrate). However, to the best of 
our knowledge, this has not been unequivocally demonstrated.  In this review, we shall focus on the 
vasodilator effects of nitrite and dietary nitrate, together with the therapeutic potential of nitrite in 
acute heart failure (AHF).  
 
4. Dietary sources of nitrite and nitrate 
4.1.  Nitrate and conversion to nitrite 
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Nitrate (NO3
-
) is a ubiquitous constituent of our environment and plays an essential role in the global 
nitrogen cycle.  Symbiotic Rhizobia bacteria located in the root nodules of leguminous plants can fix 
atmospheric nitrogen and hydrogen to produce ammonia which can be transported into the soil 
through plant roots, or by decomposition (Gilchrist, et al., 2010).  The ammonia can be converted 
into nitrite by denitrifying Nitrosomonas bacteria (and ammonia oxidizing Archaea) in the soil and 
further to nitrate by Nitrobacter.  Nitrate can be taken up from the soil through transporter channels 
in plant root cells, providing a source of nitrogen for amino acids, proteins and nucleotides essential 
for growth and development (Wang, et al., 2012).  The genetic make-up of the plant and thus the 
degree of nitrate influx and efflux via transporter channels can affect the nitrate content of the plant 
(Wang, et al., 2012).  In addition, there are several environmental impacts affecting the degree of 
nitrogen fixation, including temperature, precipitation, soil type and the extent of agricultural 
fertilizer use, and the intensity of exposure to sunlight all of which can have an impact on the nitrate 
content of plants (Seljasen, et al., 2012).   
 
4.2. Dietary sources of nitrate 
 
Green leafy vegetables are the major source of dietary nitrate. The highest reported nitrate content 
is found in rocket (arugula; range 963-4305 mg nitrate/kg) (Santamaria, et al., 1999), followed by 
radish (range 1117-2993 mg nitrate/kg) (Santamaria, et al., 1999), spinach (range 961 – 2453 mg 
nitrate/kg) (Koh, et al., 2012), beetroot (range 644-1800 mg nitrate/kg) (Tamme, et al., 2006) and 
lettuce (range 428-1766 mg nitrate/kg depending on type) (Santamaria, et al., 1999).  Cured meats 
are also a source of dietary nitrates and nitrites through the use of potassium and sodium nitrate 
and nitrite as curing/preserving agents in these products (Binkerd & Kolari, 1975; Kim & Conca, 
1990).  Drinking water is another source of nitrate (Knobeloch, et al., 2013; Nemčić-Jurec, et al., 
2013); the concentration of nitrate in drinking water will vary according to geographical location, 
regional rules regarding safe levels of nitrate in tap water, or the consumption of bottled water 
(Espejo-Herrera, et al., 2013).  
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4.3. Route of dietary nitrate after consumption 
 
Tracer studies with the stable nitrogen isotope 
15
N revealed that about 60% of an oral 
15
N-nitrate 
dose ingested is excreted via the kidneys within the following 48h; the fate of the remainder is 
unclear and assumed to be subject to metabolic transformation to other nitrogen-containing species 
(Wagner, et al., 1984).  About 25% of the circulating pool of nitrate is actively taken up from blood 
via an anion exchange channel called sialin (Qin, et al., 2012) and secreted by the salivary glands into 
saliva (Lundberg, et al., 2008).  The salivary nitrate is reduced to nitrite by commensal bacteria 
(Actinomyces and Veillonella spp.) residing on the surface of the tongue (Doel, et al., 2005; Pannala, 
et al., 2003; Tannenbaum, et al., 1976).  Nitrite is then swallowed into the stomach; in this strongly 
acidic environment nitrite is protonated to form nitrous acid (HNO2; pKa 3.15; the pKa is the pH at 
which 50% of the acid is dissociated), and can spontaneously give rise to the generation of NO 
through the following sequence of reactions: 2HNO2→H2O+N2O3 and N2O3 <->NO+NO2 (Butler and 
Feelisch, 2008), or re-enters the circulation as nitrite (Benjamin, et al., 1994; Lundberg, et al., 1994).  
This cycle is known as the ‘enterosalivary recirculation pathway’ of nitrate. 
 
Several studies have highlighted the importance of oral bacteria flora in the reduction of nitrate to 
nitrite. In earlier studies by Lundberg and Govoni (2004), the authors showed that avoiding 
swallowing after nitrate ingestion can abrogate increases in plasma nitrite (Lundberg & Govoni, 
2004).  In 2008 Govoni and colleagues expanded this work by studying the effects of commercially 
available antibacterial mouthwash on salivary and plasma levels of nitrate and nitrite following an 
oral intake of dietary nitrate (sodium nitrate) in healthy subjects.  The authors reported that rinsing 
the mouth with antibacterial mouthwash prior to ingestion of nitrate reduces the conversion to 
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nitrite in the saliva and attenuates the rise in plasma nitrite (Govoni, et al., 2008).  To corroborate 
these findings further, Petersson and colleagues (2009) explored the role of oral commensal bacteria 
in bioactivation of dietary nitrate to nitrite and NO.  Rats were treated twice daily with antiseptic 
mouthwash while they were given nitrate-supplemented drinking water (10 mmoles/L sodium 
nitrate) (Petersson, et al., 2009).  The authors reported a reduction of nitrate-reducing oral bacteria 
with a consecutive attenuation of circulating nitrite levels and the gastroprotective effects of nitrate.  
Moreover, nitrite-dependent BP lowering effects of nitrate were abolished, suggesting oral bacteria 
play an essential role in the regulation of gastrointestinal and cardiovascular function via the 
bioactivation of salivary nitrate (Petersson, et al., 2009).  Furthermore, Kapil and colleagues have 
shown in healthy volunteers that seven days treatment with an antiseptic mouthwash reduces oral 
nitrite production by up to 90%, with a concomitant decrease in plasma nitrite levels to 25% of 
control values (Kapil et al., 2013). 
 
5. Circulating nitrate and nitrite 
5.1. Relationship between plasma nitrate and nitrite 
The basal level of nitrite in the plasma of healthy individuals has been measured, with considerable 
variation between subjects and methods used,  with values ranging from a range of 50-150 nmoles/L 
to almost 1000 nmoles/L (Gladwin et al., 2000; Lauer et al., 2001; Rassaf et al., 2003; Kleinbongard, 
et al., 2003; Govoni et al., 2008). The reason for this variability is not exactly clear but is likely to 
involve methodological issues such as ongoing uptake by blood cells during the centrifugation 
process. The majority of basal nitrite originates from the oxidation of NO (Kleinbongard, et al., 2003; 
Moncada & Higgs, 1993; Rhodes, et al., 1995), with the remainder stemming from the metabolic 
conversion of dietary nitrate.  Ingestion of nitrate causes a rapid increase in circulating plasma 
nitrate within 30 minutes of consumption; the level of plasma nitrate peaks at 3 hours with levels 
remaining elevated for up to 24 hours (Kapil, et al., 2010a; McKnight, et al., 1997).  Elevations in 
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plasma nitrate are followed by a delayed increase in plasma nitrite secondary to bioconversion; 
nitrite levels rise over 1 to 2 hours and form a plateau between 2 to 6 hours after which 
concentrations decline (Kapil, et al., 2010a; McKnight, et al., 1997).  Further research has 
demonstrated maximal reduction in BP in humans at 2 to 3 hours after consumption of nitrate, 
corresponding with the point of peak plasma nitrite concentration (Petersson, et al., 2009; Webb, et 
al., 2008b).  It has also been suggested that BP reduction by nitrates acts in a dose-dependent 
manner (Kapil, et al., 2010a), although it is appreciated now that physiologically, the basal level of 
nitrite is an important contributor to blood flow regulation.   
5.2. The effect of dietary nitrate on circulatory nitrate and nitrite levels 
The Mediterranean diet is noted for its high content of vegetables, fruit and fish and has been linked 
to a lower incidence of CVD (Appel, et al., 1997; Grosso, et al., 2014; Joshipura, et al., 2001; 
Lundberg, et al., 2006) and diabetes (Salas-Salvado, et al., 2014).  The volume of vegetable 
consumption is notably higher in the Mediterranean diet than the Western diet; for example in the 
UK the average vegetable consumption per day is estimated at 160 g (Meah, et al., 1994), whilst the 
Mediterranean diet contains approximately 550 g of vegetables per day (Trichopoulou, et al., 2003).  
In terms of vegetable-provided dietary nitrate, the Mediterranean diet is estimated to contain 400 
mg nitrate per day, which is over four times the amount in a typical Western diet (estimated at 77 
mg per day) (Raat, et al., 2009). The Dietary Approaches to Stop Hypertension (DASH) diet has also 
been suggested to aid in reduction of CVD, and a review of current dietary recommendations based 
on the levels of beneficial dietary nitrate and nitrite has recently been suggested (Hord, 2011). 
Numerous studies have demonstrated that intake of nitrate-rich vegetables can increase the levels 
of circulating plasma nitrite (Kapil, et al., 2010b; Lidder & Webb, 2012; Lundberg, et al., 2006; 
Machha & Schechter, 2012).  An acute application of sodium (or potassium) nitrate in water or fruit 
juice or supplementation of the diet with nitrate has been shown to increase the levels of plasma 
nitrite (Kapil, et al., 2010a; Larsen, et al., 2006; Lundberg & Govoni, 2004). Beetroot juice has a 
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relatively high nitrate content and is frequently used in human studies as a convenient source of 
nitrate, not least because it is classified as ‘food’, simplifying the administrative effort required to 
carry out human studies in the UK and other countries. Beetroot juice consumption in healthy 
volunteers has been shown to be associated with an increase in the levels of plasma nitrate (by 16 
fold) and nitrite (by 2 fold) (Webb, et al., 2008b).  Cermak and colleagues reported a similar trend 
with regard to plasma nitrite levels in trained male cyclists. Control subjects who consumed 140 ml 
nitrate-depleted beetroot juice had plasma nitrite levels of 271 nmoles/L, whereas subjects 
consuming the same volume of beetroot juice (containing 8.7 mmoles nitrate) showed a two-fold 
higher plasma nitrite level of 532 nmoles/L (Cermak, et al., 2012).  It has also recently been 
demonstrated that nitrite/nitrate handling in humans shows sexual dimorphism: increases in plasma 
nitrate and nitrite levels as well as inhibition of platelet function after consumption of beetroot juice 
revealed a clear gender difference (Velmurugan, et al., 2013).  
The consumption of dietary nitrate from beetroot juice in healthy volunteers has been shown by 
Wylie and colleagues to increase plasma nitrate and nitrite levels in a dose-dependent manner 
(Wylie, et al., 2013).  Volunteers were given beetroot juice containing ~4.2, 8.4 or 16.8 mmoles 
nitrate; the level of circulating nitrate peaked at values of 160±43 µmoles/L, 269±92 µmoles/L and 
581±209 µmoles/L, respectively (all P <0.05).  These corresponded with increases in plasma nitrite to 
220±104 nmoles/L, 374±173 nmoles/L and 653±356 nmoles/L (all P <0.05) respective to increasing 
dose (Wylie, et al., 2013).  Furthermore, Vanhatalo et al demonstrated that continued beetroot juice 
consumption over a period of 15 days resulted in sustained elevation of plasma nitrite levels 
(Vanhatalo, et al., 2010).  The authors found that consumption of beetroot juice containing 5.2 
mmoles nitrate/day significantly elevated plasma nitrite levels by 35% 2.5 hours after ingestion, 25% 
at 5 days and 46% at 15 days, as discussed further in section 6.1. 
 
6. Effects of nitrate and nitrite on cardiovascular function 
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6.1. Effect of dietary nitrates  
As discussed in section 5.2 and depicted in table 2, several research groups have demonstrated that 
ingestion of dietary nitrate (beetroot juice) in healthy subjects results in increased plasma nitrite 
concentration via bioconversion in vivo (Cermak, et al., 2012; Kapil, et al., 2010a; Velmurugan, et al., 
2013; Webb, et al., 2008b; Wylie, et al., 2013) and substantial research efforts have focused to 
investigate the role of this bioactive nitrite on cardiovascular function (Bondonno, et al., 2012; 
Lansley, et al., 2011; Vanhatalo, et al., 2010; Webb, et al., 2008b; Wylie, et al., 2013).  For instance, 
Webb and colleagues reported a substantial reduction in systolic blood pressure (SBP) of 10.4 mmHg 
3 hours after ingestion of beetroot juice, and this effect inversely correlated with peak increases in 
plasma nitrite levels (Webb, et al., 2008b).   In order to ascertain that nitrite was indeed the carrier 
of bioactivity that accounts for the BP change, a complementary spitting study was conducted.  The 
results clearly demonstrated that spitting caused interruption of the enterosalivary recirculation of 
dietary nitrate in as much as it abolished both the rise in plasma nitrite and the decrease in BP 
(Webb, et al., 2008b).   
The consumption of nitrate rich spinach has been shown to decrease SBP, by 2.7 mmHg, and 
increase flow mediated dilatation (FMD) of the brachial artery, by 0.5%, in healthy volunteers 
(Bondonno et al., 2012).  The response of healthy volunteers to dietary nitrate via beetroot juice 
consumption has been demonstrated to show a dose-response relationship between nitrate load 
and BP.  Ingestion of beetroot juice decreased SBP and mean arterial pressure in relation to nitrate 
dose (Wylie, et al., 2013).  Decreases in diastolic blood pressure (DBP) were only found with the 
higher doses of nitrate in this study.  These changes in BP correlated with changes in plasma nitrate 
and nitrite.  The same study also demonstrated that dietary nitrate can reduce steady-state oxygen 
uptake during moderate intensity exercise and increases time to task failure (Wylie, et al., 2013).  In 
agreement with the lack of tolerance development to the vasodilator effects of nitrite alluded to 
earlier, Vanhatalo and co workers have shown that elevated plasma nitrite levels during subchronic 
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consumption of beetroot juice over a period of 2 weeks is associated with a sustained decrease in 
SBP and DBP and reduced O2 cost of submaximal exercise (Vanhatalo, et al., 2010).  Similarly, Lansley 
and colleagues showed that elevated plasma nitrate and nitrite in healthy competitive male cyclists 
improved performance in time trial cycling without alteration of VO2 max by improving exercise 
efficiency (Lansley, et al., 2011).  In contrast to these results in fit but untrained or moderately 
trained athletes, dietary nitrate supplementation has not been demonstrated to have beneficial 
effects on exercise performance or endurance in elite athletes (Christensen, et al., 2013; Peacock, et 
al., 2012).   
Overall, the results from these studies suggest that oral nitrate administration, particularly via 
beetroot juice, increases plasma nitrite levels and produces a moderate vasodilator response in 
healthy volunteers.  The effects of dietary nitrate have also been investigated in the setting of 
chronic environmental hypoxia and under pathophysiological conditions (Martin, et al., 2013; Ghosh, 
et al., 2013).  A double-blind placebo-controlled study of the effects of beetroot juice on various 
bodily functions was carried out in 28 healthy human volunteers, first at sea level and then during 5 
days at high altitude (4,559m) (Martin, et al., 2013).  The purpose of this study was to investigate 
whether the beneficial effects of nitrate on mitochondrial efficiency observed in some of the studies 
described above are maintained or might even be enhanced under conditions of reduced oxygen 
availability; if the latter was true this could be of benefit for critically ill patients suffering from 
hypoxemia.  Publication of results from this study are eagerly awaited.  
In another investigation in patients with grade 1 hypertension it has been shown that the 
consumption of beetroot juice can elevate plasma nitrite levels by 1.5 fold, with the increase being 
associated with a decrease in both SBP and DBP (Ghosh, et al., 2013).  Grade 1 hypertensives were 
classed as those with SBP between 140-159 mmHg or DBP 90-99 mmHg.  Dietary nitrate was 
consumed by drinking 250 ml of beetroot juice with nitrate concentration of 13.2 mmoles/L.  The 
SBP in these patients was shown to decrease, with peak mean fall in pressure occurring between 3 
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and 6 hours after consumption of beetroot juice at 11.2 mmHg compared to 0.7 mmHg in controls 
(Ghosh, et al., 2013).  DBP was also reduced in hypertensive patients who consumed beetroot juice, 
with a peak mean fall in pressure of 9.6 mmHg.  Similar to healthy volunteers, in hypertensive 
patients the decrease in SBP was inversely correlated with plasma nitrite but not nitrate levels.  It is 
interesting that compared to healthy volunteers, a lower dose of dietary nitrate is required to 
produce a comparable drop in SBP and DBP in hypertensive patients, perhaps because of these 
patients’ higher BP at baseline (Ghosh, et al., 2013). 
Another recent investigation is of interest in the context of discussions about the effects of nitrite 
and nitrate on BP.  In this study, the skin of 24 healthy human volunteers was exposed for 20 min to 
ultraviolet (UVA) radiation from tanning lamps. During and up to half an hour after UVA exposure 
DBP was significantly lowered by approximately 5 mmHg, and these hemodynamic changes were 
associated with opposite changes in circulating nitrate and nitrite concentrations (Liu, et al., 2014).  
These light-induced BP changes were independent of changes in vitamin D levels and suggested 
translocation of NO bioactivity from a preformed storage pool in the skin to the circulation, resulting 
in an elevation of plasma nitrite at the expense of nitrate. Surprisingly, an acute 10-fold elevation of 
circulating nitrate levels (from basal concentrations of 10.7 µmoles/L on a low nitrate diet to 108 
µmoles/L 1 hour after acute oral ingestion of sodium nitrate) did not alter the hemodynamic effects 
of UVA light. Thus, in addition to the bioactivation of nitrate to nitrite via oral commensal bacteria, 
another endogenous pool of nitrate (or a closely related NO species that can give rise to nitrite) 
appears to exist in human skin that may contribute to BP regulation in response to exposure of the 
body to UVA/sunlight.   
These studies built on earlier investigations on the effects of light on vascular tone of isolated rabbit 
aortic strips in organ baths (Furchgott et al., 1961), a phenomenon known as ‘photorelaxation’.  In 
those studies, addition of sodium nitrite to the organ bath potentiated light-induced vasorelaxation 
in an endothelium-independent manner (Matsunaga & Furchgott, 1989).  This effect of nitrite was 
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potentiated by the presence of superoxide dismutase or other O2
- 
scavengers (Matsunaga & 
Furchgott, 1989; Matsunaga and Furchgott, 1991), demonstrating the importance of the balance 
between NO and O2
-
.  Later studies in rat aortic rings showed that the release of NO from vascular 
storage forms comprising S-nitrosothiols and nitrite account for the phenomenon of photorelaxation 
(Rodriguez et al, 2003). 
6.3. Nitrite-mediated vasodilatation in physiological and pathophysiological conditions 
6.3.1. Animal studies 
The use of nitrite as a BP lowering agent dates back to the beginning of the last century (Butler & 
Feelisch, 2008).  In 1953, the ability of nitrite to act as a vasodilator was first demonstrated by 
Furchgott and Bhadrakom who showed that administration of sodium nitrite to pre-contracted 
rabbit aortic strips in vitro induced vasorelaxation (Furchgott & Bhadrakom, 1953).  In subsequent 
studies 200 µmoles/L nitrite was shown to relax rat aorta in vitro under normoxic conditions, with a 
reduction to 40 µmoles/L required under hypoxia (Modin, et al., 2001).  Whilst in a canine model 
under normoxic conditions aortic relaxation has been shown to occur with administration of nitrite 
at levels between 100 to 1000 µmoles/L (Arai, 2005). In more recent work, high micromolar to 
millimolar pharmacological concentrations of exogenously administered nitrite have been 
demonstrated to relax pre-constricted isolated blood vessels (Maher, et al., 2008; Ormerod, et al., 
2011).  Thus, when studied using isolated vascular preparations nitrite is far less potent a vasodilator 
than NO itself.  In very early work by Reichert and Mitchell (1880), potassium nitrite was found to 
exert a dose-dependent effect on pulse (at the time these experiments were conducted routine BP 
measurement was not yet part of clinical practice and only possible using somewhat cumbersome 
invasive methods (Booth, 1977); thus, pulse rate was used as a proxy for systemic effects on the 
circulation).  In man, 2 grains of potassium nitrite showed little effect on pulse (1 grain is a unit of 
mass equal to approximately 65 mg; 2 grains translate into a dose of approximately 2mg/kg).  When 
the dose was increased to 6 grains, the pulse (measured 40 minutes after nitrite administration) was 
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increased by approximately 30 beats per minute; this was associated with throbbing vessels and 
warmth to the face.  Ten grains of potassium nitrite increased pulse to an even greater extent within 
25 minutes, concurrent with flushed face and hands and a throbbing headache.  These observations 
are consistent with systemic and peripheral vasodilatation. The same authors also reported the 
effects of potassium nitrite on arterial BP in animals.  In experimental rabbits, cats and dogs, large 
doses of potassium nitrite (0.2 g in rabbits and cats and 0.5-1.0 g in dogs) caused an immediate and 
continual decrease in BP to zero.  However, a smaller dose (0.08 g) increased BP within 30 seconds 
after administration, which was followed by a decline in pressure; further administration of nitrite 
caused a similar pattern of transient increase followed by a large, sustained fall in blood pressure 
(Reichert & Mitchell 1880).  A similar dose-dependent effect of nitrite on BP has been reported more 
recently by Feelisch and colleagues (Bryan et al, 2005).  Intraperitoneally administered low doses 
(0.1 mg/kg) of sodium nitrite in rats caused a small, non-significant increase in mean arterial blood 
pressure (MAP) while higher doses (1.0 and 10 mg/kg) decreased BP by a maximum of 5% and 27% 
of controls, respectively.  Since no direct vasoconstrictor effects to nitrite have been observed in 
vitro, these studies suggest that in vivo nitrite has a dual effect on the vasculature, acting as a 
vasodilator at higher doses while eliciting a transient pressor effect at lower to intermediate doses; 
the latter may be secondary to functional interaction with other vasoactive factors. 
 
In an in vivo study in Wistar rats, it has been demonstrated that administration of either infused 
sodium nitrite, or potassium nitrite supplemented in the drinking water is associated with a decrease 
in MAP in both anaesthetized and freely moving rats (Vleeming, et al., 1997).   In a mouse model of 
ischemic (hypoxic) hind-limb, hypertensive mice showed a significantly decreased blood flow 
compared to sham operated mice, and blood flow could be recovered in both hypertensive and 
normotensive mice when treated with sodium nitrite compared to non-treated mice.  Inhibition of 
XOR prevented this recovery, suggesting a role for XOR-mediated reduction of nitrite to NO in blood 
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flow under these conditions, as suggested in in vitro studies (Amin, et al., 2012; Li, et al., 2003).  
Hypertensive mice also demonstrated a decrease in cGMP levels compared to control mice in the 
hind limb (Amin, et al., 2012).  However, treatment with sodium nitrite was found to significantly 
enhance cGMP levels; thus in this study, it was suggested that sodium nitrite could be used as a 
therapy for full recovery of blood flow.  Table 1 summarises studies to date investigating the role of 
nitrite on vasodilatation and BP in animal models. 
6.3.2. Translational studies in man 
The vasodilatory effects of nitrite infusion were later translated to healthy human volunteers.  In 
2003, Cosby and colleagues showed that sodium nitrite vasodilates the forearm vasculature when 
infused into the brachial artery (Cosby, et al., 2003).  Initially, a high dose of 36 μmoles/min (2.4 
mg/min), resulting in an approximate intravascular nitrite concentration of 200 µmoles/L, was tested 
and found to significantly increase FBF both with and without NOS inhibition by N-methylarginine (n 
= 10, P <0.01).  FBF increased further on forearm exercise during continued nitrite infusion, despite 
relative reduction in nitrite concentration due to increased blood flow.  Cosby and colleagues went 
on to test a “near-physiological” dose of 400 nmoles/min (27.6 μg/min), which significantly 
increased FBF from 3.5 ± 0.2 to 4.5 ± 0.3 ml/min/100 ml tissue (n = 10, P <0.006) at rest, and to a 
greater extent on exercise (Cosby, et al., 2003).  The authors concluded that basal levels of nitrite are 
capable of influencing resting vascular tone and subserving hypoxic vasodilatation.  In subsequent 
studies, the same group extended their previous observations with systemic nitrite.  A lower dose of 
sodium nitrite, resulting in a plasma concentration of just 350 nmoles/L, was found to cause a 
significant drop in BP in healthy volunteers.  In addition, the authors showed a dose-dependent 
increase in sodium nitrite infusion (0 to 110 µg/kg/min) increased FBF from 2.8 to 12.3 ml/min/100 
ml tissue (Dejam, et al., 2007).  
In support of an enhanced role of nitrite during hypoxia, the effects of sodium nitrite infusion during 
normoxia and hypoxia, respectively in healthy volunteers were investigated by our group (Maher, et 
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al., 2008).  Sodium nitrite was infused into the forearm brachial artery at doses from 40 nmoles/min 
to 7.84 µmoles/min (Maher, et al., 2008).  Under normoxic conditions, large decreases in forearm 
venous tone were found at doses between 784 nmoles/min and 7.84 µmoles/min, with peak 
venodilatation of 35.8% (±7.5% P <0.005) occurring at the highest infused dose of 7.84 µmoles/min.  
The forearm blood flow ratio (FBF-R: FBF corrected for control arm) was increased during the two 
highest doses of nitrite infusion at 3.14 µmoles/min and 7.84 µmoles/min, increasing from a baseline 
of 1.0 to 1.8 and 1.6 respectively (Maher, et al., 2008).  Under hypoxic conditions, FBF-R was 
enhanced following infusion of 7.84 µmoles/min and FBF-R significantly increased compared to the 
same dose under normoxic conditions (P <0.05).  We concluded that under normoxic conditions, 
nitrite was a potent vasodilator of capacitance vessels but only a modest dilator of resistance vessels 
(compared with other vasodilating agents), whilst under hypoxic conditions administration of 
exogenous sodium nitrite has a substantial relaxation effect on resistance vessels.  This may be due 
to the relatively low PO2 in the capacitance bed compared to resistance vessels under physiological 
conditions; thus the effect of nitrite on capacitance vessels will be more pronounced in normoxia, 
whereas in hypoxia nitrite demonstrates a greater effect on the resistance vessels due to the 
decrease in PO2 approaching levels (previously seen but not markedly enhanced) in the capacitance 
vasculature.  This study thus demonstrated that oxygen tension plays an essential role in 
determining the vasodilatory response to nitrite (Maher, et al., 2008), although it does not exclude 
the involvement of other contributing factors.  Table 2 summarises the recent studies that have 
investigated the efficacy and potential mechanisms of nitrite-mediated vasorelaxation and BP 
reduction in healthy and pathophysiological conditions, such as patients with hypertension or heart 
failure.  
There are noticeable discrepancies between studies regarding to the dose of nitrite and increased 
blood flow in normoxia (Cosby, et al., 2003; Lauer, et al., 2001; Maher, et al., 2008).  It has been 
proposed that in normoxia, both acetylcholine (Larrousse, et al., 2006) and bradykinin 
(Wotherspoon, et al., 2005) are more effective vasodilators, inducing increase in blood flow by three 
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to four fold, but that in hypoxia it appears that nitrite plays a dominant role.  This would suggest that 
different pathways exist to confer vasodilatation during normoxia and hypoxia and the differing 
conversion of nitrite to NO under varying oxygen tensions is thus believed to be an important 
feature integral to hypoxic signalling. 
The results on nitrite on human FBF under normoxic conditions (Cosby, et al., 2003) are in stark 
contrast to earlier findings by Lauer et al (Lauer, et al., 2001), claiming that nitrite had no direct 
vasodilator effect when intra-arterially infused, for one minute, at a rate identical to that used in the 
Cosby study.  An explanation for this discrepancy is discussed in section 7 (mechanisms of nitrite-
mediated vasodilatation). 
With regard to nitrite administration in pathophysiological conditions, a study comparing the 
intraarterial effects of nitrite administration in healthy volunteers with congestive heart failure (CHF) 
patients highlighted differing effects of nitrite administration between the two groups (Maher, et al., 
2013), with evidence of hyperresponsiveness in forearm resistance vessels in the latter (Maher, et 
al., 2013).  In contrast there was reduced venodilation in the heart failure patients, however at any 
given nitrite infusion dose the venous levels of plasma nitrite were lower in the heart failure patients 
vs controls indicating increased clearance across the forearm vascular bed and possibly explaining 
the apparent venous hyporesponsiveness (Maher, et al., 2013).  The results from these studies in 
patients with CVD highlights complications which may arise when translating results from both 
animal models and healthy human models into clinical settings, and more research in the presence 
of particular disease states may be required to fully understand how nitrite, and indeed other forms 
of therapy, can be applied for maximum patient benefit and improved clinical outcome. 
 
6.4. Role of nitrite at different oxygen tensions 
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Studies have shown that the level of nitrite in plasma appears with an apparent arteriovenous 
gradient, showing greater vasodilatation activity in the capacitance vessels under normoxic 
conditions and in the resistance vessels under hypoxic conditions (Maher, et al., 2013; Maher, et al., 
2008).  This effect has also been observed in studies of human FBF, most notably during exercise 
(Cosby, et al., 2003; Gladwin, et al., 2000).  It has been suggested that this gradient may be due to 
consumption of nitrite and NO during transit along the vascular tree (Cosby, et al., 2003; Gladwin, et 
al., 2000); the nitrite reductase activity of deoxyhemoglobin (deoxyHb) in particular is suggested to 
play a role in nitrite-NO formation as described below.   
One molecule which has garnered more attention than any other in this area is hemoglobin (Hb).  
Oxyhemoglobin (oxyHb) and deoxyHb are known as potent NO scavengers (Isbell et al., 2007; Joshi, 
et al., 2002), and have been shown to regulate the effects of NO (Griffith, et al., 1984).  However, 
only oxyHb chemically reacts with NO to form nitrate, deoxyHb binds it to form nitrosylHb. The 
balance between the different states of oxygen saturation in Hb has been suggested to contribute to 
the gradient effect between arterial and venous systems, with deoxygenation of the heme moiety 
suggested to express reductase activity with maximal efficiency around the p50, i.e. the oxygen 
partial pressure at which 50% of the hemoglobin is oxygenated (Crawford, et al., 2006; Feelisch, et 
al., 2008; Gladwin & Kim-Shapiro, 2008; Huang, et al., 2005).  It has been suggested that Hb acts as a 
nitrite reductase in the blood, with red blood cells (RBC) representing the principle source of Hb and 
a carrier of nitrite (Dejam, et al., 2005).  Hb can interact with blood nitrite via a redox process 
determined through both the heme redox potential and oxygen saturation of Hb (Shiva, et al., 2011).  
A particular balance of oxyHb to deoxyHb is required for optimal reduction of nitrite to NO, peaking 
around the p50 value.  The NO produced may then interact with mitochondrial cytochrome c oxidase 
which contains a binuclear centre to which oxygen ordinarily binds in the mitochondrial respiratory 
chain.  However, upon cytochrome c oxidase-NO binding, oxygen binding becomes inhibited, and 
mitochondrial respiration is reduced (Shiva, et al., 2011).  During hypoxia, NO-mediated inhibition of 
mitochondrial respiration is enhanced.  This process may aid the extension of oxygen gradients in 
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tissues ensuring oxygen delivery to a greater tissue area, regulating mitochondrial ROS generation 
and the action of Hypoxia Inducible Factor 1-α (Hagen, et al., 2003).  Physiologically, the vasodilatory 
action of Hb reduction of nitrite to NO is suggested to mediate the cGMP-dependent pathway of 
vasodilatation in hypoxia (Cosby, et al., 2003; Crawford, et al., 2006; Huang, et al., 2005; Jeffers, et 
al., 2005).   
The effect of oxygen tension on nitrite metabolism has also been investigated in animal 
experimental models. RBC homogenates showed the expected behaviour in as much as NO 
production from nitrite was found to be maximal around the p50 value of Hb (Feelisch, et al., 2008).  
In contrast, in rat tissue homogenates the in vitro reduction of nitrite to NO was shown to be limited 
under normoxic conditions, while nitrite to NO conversion progressively increased at lower oxygen 
concentrations in all organs, including vascular tissue (Feelisch, et al., 2008). This metabolic activity 
was associated with an increase in the formation of nitrosated and nitrosylated products in vivo.  
The formation of NO from nitrite was found to be largely enzymatic in nature as it was sensitive to 
heat inactivation and blockage of thiol groups (Feelisch, et al., 2008), supporting earlier studies 
implicating heme and thiol-containing reductases in this process (Bryan, et al., 2005).  Data from a 
more recent in vivo study carried out in rats suggest that acute hypoxic vasodilatation is largely 
mediated by NO metabolites rather than by free NO from Hb-mediated nitrite reduction (Umbrello, 
et al., 2014). 
The step-wise reduction of nitrate to nitrite and nitrite to NO has been demonstrated under anoxic 
conditions in vitro with a role for nitrate/nitrite reductase xanthine oxidase (XO) (Li, et al., 2003).  
The authors of this study also found that nitrite and NO production was pH-dependent with 
maximum observable NO production at pH 5.0, suggesting that XO reduces nitrate to nitrite and NO 
under acidic conditions, as associated with CVD (Li, et al., 2003). 
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7.  Mechanisms of nitrite-mediated vasodilatation 
Much of our current understanding about nitrite’s mode of action as a vasodilator is based on animal 
experimental work and observed associations of changes in circulating plasma concentrations and 
blood flow and/or pressure at pharmacological doses; other pieces of information are derived from 
in vitro studies with isolated proteins or cultured cells.  Considerably less information is available on 
the mechanism of vasodilatation by nitrite in human tissue and the role, if any, of endogenous nitrite 
for human physiology.  The fact that nitrite can relax isolated segments of precontracted vascular 
tissue in organ baths does not necessarily mean that it is involved in the regulation of BP.  Part of the 
paucity of mechanistic information is due to the fact that monitoring the rather low concentrations 
of endogenous nitrite requires specific analytical equipment such as HPLC or gas phase 
chemiluminescence, which is not available in every laboratory; another reason is that our current 
understanding of basic processes including nitrite/nitrate uptake, processing and excretion at the 
cellular and whole organism level is incomplete.  Moreover, while biochemically interesting in 
principle some in vitro findings obtained with high nitrite concentrations under complete anoxia are 
likely to be of limited relevance to physiology.  The lack of pharmacological tools such as specific 
‘nitrite scavengers’ is also a limiting factor.  The extrapolation of animal experimental data to human 
physiology requires particular care – not everything that looks promising in the animal experimental 
setting is ultimately going to work in humans. 
It is important to acknowledge that no ‘nitrite receptor’ has yet been described; thus, there is no 
mechanistic basis for a direct coupling of a nitrite recognition site to a down-stream signalling event 
in smooth muscle to trigger vasodilatation.  Therefore, the vasodilator effects of nitrite are not, at 
least at present, known to be a consequence of interaction with a specific receptor in vascular tissue; 
with no ‘nitrite receptor’ as target, there is likely no simple concentration-response relationship for 
its biological effect either.  Although it cannot be excluded at present that nitrite may affect 
processes coupled to the transport of other anions in the vasculature (a process that could 
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conceivably affect vascular tone), all evidence available to this date suggests that nitrite has to be 
metabolized to NO, or an NO-like species, in order to exert a biological effect.  This process appears 
to require the presence of a sulfhydryl group and a heme moiety (Bryan, et al., 2005). There is no 
agreement in the literature as to whether nitrite is metabolised intracellularly or bioactivated in the 
extracellular space. Nitrite may require prior entry to the tissue first before it can act as a 
vasodilator. In this case, the plasma/tissue concentration gradient would seem to be important, but 
transport may well be via a carrier-facilitated uptake, with competition by other anions – little is 
known about any of this. Once inside the vascular tissue, nitrite may interact with one of the 
enzymes described below to become reduced to NO (or N2O3) and/or become biotransformed to 
nitroso and/or nitrosyl species before being able to interact with sGC to produce cGMP.  However, 
nitrite transport into cells may not be required in all cases as it has recently been shown that nitrite 
reduction can also occur through red blood cell (or endothelial cell) nitrite reductases such as XOR 
(Ghosh et al., 2013) to mediate a vasodilatory response. 
A surprisingly large number of different proteins have been identified that can reduce nitrite to NO 
in vitro, and detailed recent reviews on this topic are available (Kim-Shapiro & Gladwin, 2013; van 
Faassen, et al., 2009; Kapil, et al., 2010b; Lundberg and Weitzberg, 2010).  However, there is neither 
agreement in the literature as to which of these potential nitrite bioactivation processes are the 
most relevant for vasodilatation (or any other biological process), nor do we understand the reason 
for this particularly high degree of redundancy.  In principle, the processes involved are 
chemical/non-enzymatic or enzymatic, with different pH optima for nitrite reduction depending on 
the nature of the proteins involved.  Many of the enzymatic pathways demand rather low 
concentrations of oxygen to reduce nitrite efficiently. In fact, oxygen appears to be a highly effective 
inhibitor of tissue ‘nitrite reductase’ activity (Feelisch, et al., 2008).  Thus, hypoxia does not 
‘stimulate’ nitrite reduction, it is rather that lower levels of oxygen result in less inhibition.  
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The simplest chemical pathway of NO generation from nitrite involves disproportionation of the 
corresponding acid, HNO2.  This pathway is probably not of much relevance for nitrite bioactivation 
in vascular tissue, unless it is rendered hypoxic for a prolonged period of time.  Both Hb (Basu, et al., 
2007) and carbonic anhydrase (Aamand, et al., 2009) have been reported to possess nitrite/nitrous 
acid anhydrase activity, a reaction in the course of which N2O3 is formed, eventually giving rise to NO 
and NO2.  While the former could theoretically provide a convenient way of exporting nitrite-derived 
NO from RBCs under hypoxic conditions, recent animal experimental results suggest that the 
majority of hypoxic vasodilatation is not mediated by Hb-mediated nitrite reduction (Umbrello, et 
al., 2014).  The nitrite reductase activity of carbonic anhydrase appears to be linked to the coupling 
of cerebral blood flow and metabolic activity in response to visual stimulation (Aamand, et al., 2009; 
Aamand, et al., 1985).  
It would perhaps be desirable to group proteins according to the mechanism involved in nitrite 
reduction, but this is not known for all proteins to date. Moreover, a single protein may employ 
several different pathways to reduce nitrite to NO; in the case of Hb and myoglobin (Mb) these have 
been proposed to include R-state catalysis, oxidative denitrosylation (of the intermediate NO-heme 
product formed), and the above nitrite anhydrase reaction (Gladwin, et al., 2009).  Alternatively, a 
thiol group in Hb may become nitrosated during deoxygenation/reoxygenation, by a mechanism 
involving NO-heme formation from nitrite, to form a nitrosothiol (SNO-Hb) which may serve as NO-
carrier (Angelo, et al., 2006), or that nitrite is reduced by the eNOS expressed in RBCs (Cortese-Krott, 
et al., 2012) under some conditions. Thus, even for some of the most extensively studied proteins 
the precise mechanisms involved remain unclear.  As a result, proteins are typically categorised 
according to the principle reaction they are known to catalyse (which may not always match with 
the mechanism involved in nitrite bioactivation, but that is another matter), or the prosthetic group 
they carry.  According to this principle, the proteins involved in nitrite reduction can be divided into 
two broad groups: heme-based proteins and molybdopterin-based oxidoreductases.  The two best 
studied examples of the former are Hb and Mb, and both have been claimed to play major roles in 
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nitrite bioactivation (Kim-Shapiro & Gladwin, 2013; Shiva, et al., 2007a; Totzeck, et al., 2012b), in 
particular under hypoxic conditions (Crawford, et al., 2006; Hendgen-Cotta, et al., 2014).  Less well 
studied members of this group include neuroglobin and cytoglobin, cytochrome C and cytochrome C 
reductase, cytochrome P450, and the endothelial NOS isoform.   
The most recent member of the heme-based nitrite reductases is cystathionine beta-synthase (CBS) 
(Gherasim, et al., 2014), a key enzyme of the transsulfuration pathway involved in homocysteine 
metabolism, glutathione production, and formation of hydrogen sulphide (H2S).  As with other 
heme-based reductases, NO-heme formation leads to autoinhibition of the enzyme, representing an 
interesting new facet of the NO/H2S cross-talk.  Members of the molybdopterin-based 
oxidoreductases shown to reduce nitrite to NO involve XO (Cantu-Medellin & Kelley, 2013), aldehyde 
oxidase (Li et al., 2008), and sulfite oxidase (Wang, et al., 2011).  Many of the above proteins have 
been studied in relative isolation; their importance in mediating the vasorelaxant response to nitrite 
has been assessed using pharmacological inhibitors (of varying specificity) and, in some cases, 
knockout mice. Yet most papers are limited to the investigation of one specific pathway, and reading 
the literature one could easily get the impression that they are all equally important, or solely 
responsible for the effects of nitrite under some conditions.  Figure 1 illustrates the nitrite-derived 
NO signalling in the vascular system.  
Let us now revisit the discrepancy between the in vivo results presented by the groups of Lauer et al 
and Cosby et al. mentioned in section 6.3. Why did apparently identical solutions of sodium nitrite in 
saline produce no vasodilatation whatsoever in one case (Lauer et al, 2001) and marked increases in 
FBF in the other (Cosby et al, 2003)  Notwithstanding minor differences in blood flow at baseline, 
intravascular nitrite concentrations achieved must have been of comparable magnitude. The 
explanation may be linked to differences in infusion times (and thus total amounts of nitrite 
delivered). If the same concentration of a nitrite stock solution is infused at the same rate into the 
vasculature then the total amount of bioactive drug (nitrite) scales with the duration of infusion. In 
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the earlier studies by Lauer et al infusions were limited to 1 min (during which time no changes in 
blood flow were observed, consistent with a lack of direct vasodilator effect of nitrite) whereas in 
the Cosby study infusions continued for as long as 5 min. As nitrite delivery continues, increasing 
amounts of nitrite enter the systemic circulation, gaining access to tissues and blood cells; if the rate 
of administration exceeds that of elimination, nitrite and its metabolic products (including nitroso 
and nitrosyl species) begin to accumulate in the vasculature and relaxation ensues. A number of 
animal experimental results (Bryan et al, 2004; Nagasaka et al, 2008; Perlman et al, 2009) indicate 
that plasma concentrations of nitrite are uncoupled from those in tissues, suggesting the 
involvement of additional steps that regulate circulating nitrite concentrations. Thus, short-term 
infusions of nitrite may differ in effects on pressure and flow from those of longer lasting infusions, 
and total amounts of nitrite delivered may be as important as local concentrations achieved. If this 
was true, in vivo nitrite administration regimes might better be compared on the basis of cumulative 
amounts administered rather than circulating concentrations measured – time will tell. 
 
While initial efforts focussed on the identification of potential nitrite bioactivation pathways (often 
under very specific reaction conditions with exclusion of oxygen), many more ‘leads’ emerged than 
anticipated and likely in operation under physiological conditions.  There is a growing appreciation 
that reduction of nitrite to NO may be mediated by different pathways under different physiological 
conditions and that the effects of nitrite are sometimes mediated by metabolites other than NO.  
Moreover, most of the known chemistries proposed to be involved in these processes are rather 
slow, questioning their overall relevance for physiological regulation.  Ultimately, confirmation for 
the involvement of candidate pathways of bioactivation will require in vivo experimentation. To this 
end, Hendgen-Cotta et al. (2014) have recently demonstrated a role for Mb in nitrite-mediated 
vasodilatation under hypoxic conditions.  In addition, there is increasing evidence that nitrite 
reduction may occur via blood borne protein mediated mechanisms such as RBC eNOS, as 
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demonstrated by Webb et al. (2008a) and Wood et al. (2013), as opposed to or in addition to the 
currently favoured vascular tissue-derived NO.   Also of interest is recent work by Umbrello et al. 
(2014) who have demonstrated that short-term hypoxic vasodilatation may be mediated by 
bioactive NO metabolites rather than by free NO.  These recent findings are of great interest in 
terms of the perceived “physiology” of nitrite but require further substantiation and independent 
confirmation by other groups.  The above observations do not exclude the possibility that nitrite 
bioactivation occurs through as yet unknown enzymatic or chemical mechanisms.  There is also 
much to be considered physiologically in terms of cross-talk between different enzymatic pathways, 
such as regulation of activity, which will impact on the effects of nitrite and rate of NO/metabolite 
production and clearance, and even other chemical entities (carbon monoxide and hydrogen sulfide, 
for example) much of which has yet to be discovered in vivo. 
 
8.  Potential therapeutic role of nitrite in acute heart failure 
Acute emergence or deterioration of heart failure, with or without the associated development of 
acute pulmonary edema and the potential need for assisted ventilation, remains a frequent cause of 
hospital admission with associated morbidity and mortality. Furthermore, there is currently no 
consensus as to the optimal management of AHF, despite emergence of a large number of potential 
forms of pharmacotherapy.  Many patients with AHF have pre-existent impairment of left ventricular 
systolic function, and decompensation may reflect intercurrent infection, onset of tachyarrhythmias, 
recurrent myocardial ischemia and/or poor compliance with prescribed therapy. 
Traditionally, AHF has been treated with therapeutic regimens based on the use of diuretics, but it 
has emerged over the past 20 years that a therapeutic approach centred on the intravenous 
administration of NO donors to all patients with associated pulmonary edema, together with 
inclusion of NO donors in the treatment of patients with less severe hemodynamic decompensation, 
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may have substantial advantages (Beltrame, et al., 1998; Cotter, et al., 1998).  On this basis, 
intravenous infusion of organic nitrates such as GTN or isosorbide dinitrate is commonly utilized as a 
component of therapy for AHF with pulmonary edema.   
While organic nitrate infusions are generally helpful in the immediate treatment of such patients, 
they impose a number of difficulties.  Firstly, organic nitrates such as GTN are absorbed by the 
plastics material of common intravenous infusion set (bags and infusion tubing) (Cawello and Bonn, 
1983; Hansen and Spillum, 1991).  Hence, unless specialised infusion apparatus is used, it is 
uncertain whether patients are receiving appropriate GTN infusion rates.  Secondly, all organic 
nitrates are potentially prone to the development of nitrate tolerance during long-term therapy: this 
is manifest as progressive attenuation of hemodynamic and anti-aggregatory responses to the 
administered nitrate, with cross-tolerance to other organic nitrates.  While some investigators have 
suggested that nitrate tolerance is also associated with worsening of endothelial dysfunction and 
attenuation of responsiveness to endogenous NO (that is, cross-tolerance to endothelial NO), overall 
evidence is more consistent with the concept that nitrate tolerance is engendered primarily by 
failure of enzymatic release of NO from organic nitrates (Sage, et al., 2000).  As the probability of 
emergence of nitrate tolerance is determined essentially by the combination of infusion rate and 
duration of exposure (Henry, et al., 1989), this imposes the need to utilize organic nitrate infusions 
briefly and with the lowest possible infusion rates. 
On the other hand, patients with heart failure, whether acute or chronic, display tissue resistance to 
the effects of NO (for review see (Chirkov & Horowitz, 2007)), related primarily to dysfunction of sGC 
and “scavenging” of NO by O2
- 
. Hence low organic nitrate infusion rates may not achieve ideal 
hemodynamic responses.  Resorting to intermittent dosing regimes, as sometimes used for 
antianginal treatment, is impractical for AHF as it bears the risk of inappropriate therapeutic 
coverage during drug-free intervals. 
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Infusion of nitrite as a means of treatment for AHF offers a theoretical means of circumventing many 
of the problems associated with organic nitrate infusion. The relative selectivity for the (hypoxic) 
venous capacitance vessels and pulmonary vasculature would be an attractive profile in the 
management of decompensated heart failure.  Furthermore the apparent lack of tolerance (Haas, et 
al., 1999; Dejam, et al., 2007) would be an additional advantage over organic nitrates (Sage, et al., 
2000).  However sustained high dose nitrite infusion can cause methemoglobinemia and hemolysis 
(Pluta, et al., 2011).  To date there have been no large scale studies of nitrite infusion in heart failure. 
 
9. Potential toxicity of nitrate and nitrite 
Although the role of nitrate and nitrite in cardiovascular health is becoming increasingly apparent, 
the ingestion of these anions has also been linked to health concerns.  There is an abundance of 
literature on the subject, so we only provide a few pointers for balance here. Dietary nitrate and 
nitrite can form N-nitrosamines, and countless animal studies have documented low-molecular 
weight N-nitrosamines to be carcinogenic in numerous organ systems when ingested orally over 
prolonged periods (Archer, 1989; Tricker, 1997; Mirvish, 1995). In humans, the role of dietary intake 
of N-nitrosamine compounds and their precursors in the development of cancer is of ongoing 
interest, but relies largely on observed associations between the intake of certain food classes and 
cancer risk/death; in many cases, nitrite and nitrate (or preformed N-nitroso compound) intakes 
were not quantified but estimated using food frequency questionnaires (considering the level of 
geographical and seasonal variations in nitrate content alone this is not without problems). Some 
more recent meta-analyses and careful re-assessments of cancer risks and dietary habits in larger 
cohorts find no association between nitrite and/or nitrate intake and cancer development, but risks 
may vary depending on cancer types and organs involved. Most likely, matters are much more 
complicated than hitherto assumed, with environmental and life-style related factors playing 
important modulatory roles. One very recent study (Delavalle et al, 2014) suggests that colon cancer, 
for example, develops not as a result of increased nitrate intake but is secondary to reduced 
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antioxidant levels (vitamin C, for example, can inhibit nitrosation). Teleologically, it is difficult to see 
why moderate intake levels of nitrite and nitrate would be linked to cancer development as they 
occur endogenously in astonishing concentrations in some compartments (e.g. in saliva) and thus 
are part of our normal body physiology. 
   
Another concern about nitrate is methemoglobinemia. Bacteria in the mouth and gut convert nitrate 
into nitrite, and nitrite reacts with Hb to produce methemoglobin, which is no longer able to 
transport and release oxygen effectively to tissues. Most cases of methemoglobinemia were 
reported in the 1940’s where methemoglobinemia or “baby blue syndrome” was seen in infants fed 
formula with nitrate contaminated well-water (Powlson et al, 2008). It was later suggested that 
methemoglobinemia was not caused by nitrate but by fecal bacteria contamination in the well-water 
or bacterial nitrate reduction in vivo that may have caused the intestinal infection, and this may have 
been responsible for the nitrate-induced methemoglobinemia in the infants (Hanukoglu & Danon 
1996; Ward et al, 2005).  Of interest, nitrate was used in very high doses (often for weeks) at the 
beginning of the last century as a diuretic (Butler & Feelisch, 2008). Recent studies by Pluta and 
colleagues (2011) have investigated the safety and feasibility of long-term intravenous infusion of 
sodium nitrite in healthy subjects. The authors demonstrated that acute intravenous infusion of 
sodium nitrite was tolerated up to a maximum dose at 267 µg/kg/hour, and that the dose-limiting 
toxicity was reached at 446 µg/kg/hour. Toxicity included a transient asymptomatic decrease of MAP 
and an increase of methemoglobin (above 5%). Overall, the authors suggested that nitrite could be 
‘safely infused intravenously at defined concentrations for prolonged intervals’.   
 
Finally, although there are reports to suggest that nitrate and nitrite are harmful when ingested in 
excess, the same is true for about every other substance essential to mammalian life including 
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glucose, fat and oxygen. It is important to establish limits at which the harm may outweigh the 
potential benefits, and further research is warranted to investigate what these limits may be for 
nitrate and nitrite. The extensive monograph by L’hirondel & L’hirondel (2002) and several recent 
articles (Lundberg et al, 2004; Bryan et al, 2012; Kapil et al, 2014) provide a more detailed 
information for further reading about the potential harmful effects of nitrate and nitrite.  
10.  Summary and conclusions 
Nitrite apppears to have considerable potential as a therapeutic agent to increase the bioavailability 
of NO under certain conditions such as in hypoxia, where endogenous NO production via the L-
arginine-NOS-NO pathway may be compromised.  Thus, nitrite could conceivably be applied in 
conditions such as heart failure due to its vasodilatory capacity, apparently without the risk of 
development of tolerance and headache as documented with organic nitrate treatment, making 
nitrite perhaps a more acceptable alternative.  Oral nitrate administration would appear to 
represent an attractive vehicle for nitrite delivery in vivo. The beneficial vasodilatory effects 
apparent with nitrate and nitrite consumption through dietary sources may promote vascular health 
and ward off CVD.  Nitrite therapy is a rapidly expanding area with great potential for improved 
clinical outcome in patients, however caution is advised in the translation of results obtained in 
animal experimental models to the clinical setting. A recent multi-centre, double-blind, placebo 
controlled clinical trial showed that nitrite was ineffective when administered intravenously 
immediately prior to PPCI in patients presenting with first acute STEMI (Siddiqi et al, 2014). 
Therefore, we need to be mindful of differences between animal and human physiology as well as 
inter-individual differences in responsiveness to nitrite between subjects.  Moreover, the handling of 
nitrite (and nitrate) may differ between health and disease, posing additional challenges to 
effectiveness and applicability of the administered treatment. 
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Figure and table legends 
Figure 1. The role of nitrite-derived nitric oxide in the vasculature. During normoxia, L-arginine is 
metabolized  in endothelial cells via nitric oxide synthase (NOS) to nitric oxide (NO) to induce 
vasodilatation. Under normal physiological pH and oxygen tension, nitrite (NO2
-
) is an endogenous 
substance produced via the oxidation of NO (principally by cytochrome c in cells and ceruloplasmin 
in blood). During hypoxia and acidosis, NO2
- 
can be bioconverted to NO via multiple nitrite 
reductases, including deoxyhemoglobin, myoglobin, xanthine oxidoreductase, and endothelial NOS 
to mediate hypoxic vasodilatation.  cGMP (cyclic guanosine monophosphate); sGC (soluble guanylyl 
cylase); NO3
- 
 (nitrate).
 
 
Table 1: Experimental studies investigating the efficacy of nitrite on vasorelaxation and blood 
pressure.  A summary of in vitro and in vivo studies that have evaluated the efficacy as a vasodilator. 
Adenosine tri-phosphate (ATP), aldehyde deydrogenase 2 (ALDH2), blood pressure (BP), cyclic 
guanosine monophosphate (cGMP), deoxyhemoglobin (deoxyHb), endothelial nitric oxide synthase 
(eNOS), glyceryl trinitrate (GTN), hemoglobin (Hb), mean arterial pressure (MAP), myoglobin (Mb), 
nitric oxide (NO), oxyhemoglobin (oxyHb), red blood cells (RBC), soluble guanylate cyclase (sGC), 
systemic arterial pressure (SAP), xanthine oxidase (XO), xanthine oxidoreductase (XOR). 
 
Table 2: Nitrite efficacy in humans and regulation of vasodilatation and blood pressure.  A 
summary of recent studies that have evaluated the efficacy of nitrite as a vasodilator in healthy 
subjects, hypertensive and heart failure patients. Acetylcholine (ACh), blood pressure (BP), 
congestive heart failure (CHF), cyclic guanosine monophosphate (cGMP), deoxyhemoglobin 
(deoxyHb), diastolic blood pressure (DBP), flow-mediated dilatation (FMD), forearm blood flow 
(FBF), New York Heart Association (NYHA), nitric oxide (NO), nitric oxide synthase (NOS), mean 
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arterial pressure (MAP), red blood cells (RBC), systolic blood pressure (SBP), xanthine oxidoreductase 
(XOR). 
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Table 1 
Species  Condition/model  Nitrite reductase  Dose/ route/timing 
administration of nitrite  
Results  Reference  
Mouse  Hypertension model. 
Wild type compared to 
eNOS -/- mice  
eNOS from RBC (non-
endothelial)  
Endogenous systemic 
nitrite levels  
eNOS -/- mice displayed 
lower plasma nitrite 
concentrations compared 
to wild type. Provides 
evidence that circulating 
blood eNOS plays a role 
in nitrite homeostasis 
and BP regulation during 
physiological conditions  
(Wood, et al., 2013)  
Rat  Hypertension model. 
Used spontaneous 
hypertensive & 
normotensive Wistar 
Kyoto rats  
XOR derived from RBC's  Potassium nitrite 
administered as bolus 
doses between 1-30,000 
x 10-9 mol/kg  
Nitrite decreased BP in a 
dose-dependent manner. 
The effect of nitrite was 
greater in spontaneously 
hypertensive rats 
compared to 
normotensive and was 
abolished with 
allopurinol (XOR 
inhibitor). The study 
showed that this effect 
was associated with an 
increase in erythrocytic 
XOR expression but not in 
the blood vessel wall  
(Ghosh, et al., 2013)  
Mouse  Assessment of hypoxia 
vasodilatation in Mb wild 
type and deficient mice  
Mb  Assessed endogenous 
and exogenous nitrite.  
For exogenous studies 
1.67 or 16.7 μmol/kg was 
used  
Mb expression in vascular 
smooth muscle 
contributes to nitrite-
mediated hypoxic 
vasodilatation ex vivo and 
in vivo. This effect was 
mediated via Mb-induced 
activation of 
(Totzeck, et al., 2012a)  
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NO/sGC/cGMP pathway  
Rat  Normotensive compared 
to hypertensive rats. 
Assessed whether gastric 
pH reduced hypotensive 
effects  
-  2 protocols used:  
(1) oral (gavage) 
administration sodium 
nitrite (1 - 45 mg/kg) 
compared with  
(2) intravenous sodium 
nitrite (1-15 mg/kg)  
Increased gastric pH 
caused by omeprazole 
reduced the hypotensive 
effect of nitrite in both 
normotensive and L-
NAME-hypertensive rats. 
The study concluded that 
the hypotensive effect of 
sodium nitrite was partly 
due to bioconversion to 
NO under acidic 
conditions of the 
stomach  
(Pinheiro, et al., 2012)  
Mouse  Assessed the effects of 
dietary nitrate on XOR 
and eNOS in pulmonary 
hypertension model  
eNOS and XOR  Supplementation of 
drinking water with 
either potassium nitrate 
(15 mmol/L or 45 
mmol/L) or potassium 
nitrite (0.6 mmol/L)  
Dietary nitrate, but to 
lesser extent dietary 
nitrite, causes pulmonary 
dilatation and prevents 
vascular remodelling and 
right ventricular 
hypertrophy. These 
effects were dependent 
on eNOS and XOR 
reduction of nitrite to NO  
(Baliga, et al., 2012)  
Ovine  Assessed the effects of 
nitrite on pulmonary and 
systemic arterial vascular 
resistance in newborn 
lambs  
DeoxyHb  Inhalation of sodium 
nitrite via nebulizer (0.87 
mol/L) compared to 
intravascular nitrite 
infusion 5 mg/kg/hour  
Inhaled nitrite elicited 
pulmonary vasodilatation 
through NO mediated 
mechanism. Intravascular 
nitrite did not elicit 
pulmonary 
vasodilatation. Inhaled 
nitrite produces NO in 
the airway and 
parenchymal lung tissue 
(Blood, et al., 2011)  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
57 
 
to mediate vasodilatation 
and this was independent 
of deoxyHb in the 
pulmonary circulation  
Mouse  Model of vascular 
endothelial dysfunction 
associated with age using 
old (26-28 month) mice 
compared to young (4-6 
month) mice.  
-  Supplementation of 
sodium nitrite in drinking 
water (50 mg/L) for three 
weeks  
Sodium nitrite restored 
endothelium-dependent 
dilatation in old mice via 
increase in NO 
bioavailability. Nitrite 
reversed vascular 
endothelial dysfunction 
associated with age  
(Sindler, et al., 2011)  
Mouse  Assessed the effects of 
nitrite on vascular Mb  
Mb  Sodium nitrite  Vascular Mb plays an 
essential role in nitrite-
dependent 
vasodilatation.  
(Ormerod, et al., 2011)  
Rat  Assessed the role of GTN 
and sodium nitrite in the 
pulmonary vascular bed  
ALDH2 and XOR  Intravenous injection 
sodium nitrite (10-100 
μmol/kg)  
Administration of GTN or 
sodium nitrite caused a 
decrease in pulmonary 
and SAP. Response to 
GTN or sodium nitrite 
was attenuated by 
cyanamide (ALDH2 
inhibitor). The effect of 
sodium nitrite, but not 
GTN, was also attenuated 
by allopurinol (XOR 
inhibitor)  
(Badejo, et al., 2010)  
Rat  Assessed the mechanism 
of nitrite and RBC-
mediated vasodilatation  
-  Intravenous injection 
sodium nitrite 10 
μmol/kg  
Vasodilatation via nitrite 
could be mediated 
through nitrite 
enhancement of ATP 
release from RBC  
(Cao, et al., 2009)  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
58 
 
Rabbit  Assessed the effect of 
nitrite on NO-dependent 
and independent 
vasodilatation pathways 
during hypoxic conditions  
Aldehyde oxidase, eNOS, 
XO  
Nitrite  During hypoxia, nitrite-
induced vasorelaxation 
was largely due to nitrite 
reduction by aldehyde 
oxidase to NO, but was 
also partly mediated via 
the cyclooxygenase 
pathway. XO or eNOS did 
not play a role in this 
study  
(Pinder, et al., 2009)  
Rat  Effect of carbonic 
anhydrase on nitrite-
induced vasodilatation 
during normoxia and 
hypoxia  
Carbonic anhydrase  Sodium nitrite  Carbonic anhydrase 
reacts with nitrite to 
produce NO during low 
pH conditions. This 
reaction induced 
vasorelaxation during 
normoxic and hypoxic 
conditions  
(Aamand, et al., 2009)  
Rat  Investigated the 
importance of oral 
microflora and dietary 
nitrate in regulation of BP 
and gastric mucosal 
defence  
-  Supplementation of 
drinking water with 
either sodium nitrate 10 
mM (~140 mg/kg/day) or 
sodium nitrite 1 mM (~14 
mg/kg/day)  
Mouthwash reduced 
nitrate-reducing oral 
bacteria and caused a 
reduction in circulating 
nitrite. BP reduction was 
observed after nitrate 
supplementation in the 
absence of mouthwash. 
Gastroprotectitive effect 
of nitrate was reduced in 
rats treated with 
mouthwash  
(Petersson, et al., 2009)  
Rat  Assessed the role of XOR 
and ALDH2 in nitrite-
mediated effects on BP in 
rats  
XOR and ALDH2  Intravenous 
administration of sodium 
nitrite  
Nitrite decreased mean 
SAP. The decreases in 
mean SAP in response to 
sodium nitrite was 
attenuated by both XOR 
and ALDH2 inhibitors. 
(Golwala, et al., 2009)  
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The study suggested that 
both XOR and ALDH2 
work in parallel to 
mediate nitrite 
conversion to vasoactive 
NO  
Rat  Assessed the role of XOR 
in response to sodium 
nitrite in the pulmonary 
vasculature  
XOR  Intravenous injection of 
sodium nitrite 10 - 100 
μmol/kg  
Intravenous 
administration of nitrite 
decreased pulmonary 
arterial pressure and SAP 
The responses to nitrite 
was attenuated by 
allopurinol (XOR 
inhibitor). This study 
suggests that XOR is the 
major enzyme reducing 
nitrite to vasoactive NO, 
and that this mechanism 
is not modified by 
hypoxia  
(Casey, et al., 2009)  
Canine  Assessed the 
physiological effects of 
sodium nitrite and 
determined whether the 
effect was influenced by 
cell-free plasma Hb 
during intravascular 
hemolysis  
Hb  Intravenous infusion of 
sodium nitrite 27.5 
mg/hour for 6 hrs  
Nitrite reductase activity 
of Hb caused an 
increased vasodilatory 
response to nitrite during 
low levels of hemolysis  
(Minneci, et al., 2008  
Rat  Assessed effect of nitrite 
on BP in vivo and 
vasorelaxation in isolated 
aorta in vitro  
Hb  In vivo: intravenous 
injection of sodium 
nitrite (10 μM - 2 mM)  
In vivo: Sodium nitrite 
caused a dose dependent 
decrease in BP In vitro: 
During aerobic 
conditions, XOR , 
mitochondrial electron 
transport, cytochrome 
P450 and NOS inhibitors 
(Alzawahra, et al., 2008)  
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did not effect nitrite-
mediated vasorelaxation. 
The study suggested that 
heme proteins and/or 
sGC pathways are 
involved in nitrite 
mediated effects  
Non-human primates  Assessed the 
physiological and 
pharmacological effects 
of sodium nitrite on 
vasodilatory responses  
XOR and deoxyHb  Sodium nitrite 12.5 
μg/kg/min over 24 hours 
for 14 days  
Sodium nitrite was a 
potent vasodilator at 
near-physiological 
concentrations. Nitrite 
was reduced to NO by 
intravascular reactions 
with deoxyHb. In 
contrast, XOR inhibition 
did not attenuate the 
nitrite-induced 
vasodilatation  
(Dejam, et al., 2007  
Rat  Assessed effect of Hb 
oxygen saturation on 
vasodilatation  
OxyHb/  
DeoxyHb  
Sodium nitrite increasing 
concentration 0.01 to 
1000 μM  
Deoxygenation of Hb was 
associated with nitrite-
dependent vasodilatation 
which was inhibited by 
NO scavenger (c-PTIO) 
under both normoxic and 
hypoxic conditions. In 
contrast, NO dependent 
vasodilatation (via NO 
donor NONOate) was 
inhibited by both oxyHb 
and deoxyHb suggesting 
unique interaction of 
nitrite with Hb. This study 
suggested that NO 
homeostasis was 
regulated by balance in 
NO 
(Isbell, et al., 2007)  
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scavenging/generating 
activity through oxygen 
saturation of Hb  
Rat  Effect of nitrite 
dependent vasodilatation 
in hypoxia (in vitro)  
Hb, XO, mitochondrial bc1 
complex  
Sodium nitrite in 
cumulative additions 0.01 
to 300μM  
Nitrite induced a 
concentration dependent 
effect on vasodilatation. 
The vasoactive effect of 
nitrite during hypoxia 
was attenuated on 
inhibition of sGC but was 
unaffected by inhibition 
of xanthine oxidase or 
the mitochondrial bc1 
complex. In addition, 
deoxygenation of Hb did 
not appear to enhance 
vasoactivity of nitrite  
(Dalsgaard, et al., 2007  
Rat  Hypoxic pulmonary 
vasoconstriction in 
isolated perfused lungs  
Hb  Lungs perfused with 
sodium nitrite buffer 
increasing concentration 
(250 nM to 1 mM) with 
or without RBC's  
In isolated perfused 
lungs, low concentrations 
of nitrite inhibited 
hypoxic pulmonary 
vasoconstriction, possibly 
due to the release of NO 
rather than the direct 
effect of nitrite on 
vascular smooth muscle. 
However, physiological 
concentrations of RBCs 
and free Hb prevented 
nitrite inhibition of 
hypoxic pulmonary 
(Deem, et al., 2007)  
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vasoconstriction thus 
raising doubts for the 
role of RBCs in nitrite-
mediated vasodilatation 
in the pulmonary 
circulation  
Canine  In vivo model of acute 
pulmonary 
thromboembolism  
-  Intravenous infusion of 
nitrite (6.75μmol/kg over 
15 min then at 
0.28μmol/kg/min for 120 
minutes)  
Infusion of nitrite 
increased plasma nitrite 
levels with a dose-
dependent decrease in 
pulmonary vascular 
resistance index, 
systemic vascular 
resistance index, and 
MAP  
(Dias-Junior, et al., 2006)  
Rat and rabbit  Hypoxic vasodilatation in 
isolated thoracic aortas  
Hb  Sodium nitrite 0.01 - 
1000μM  
This study showed that 
nitrite induced 
vasodilatation and 
supported the role of RBC 
Hb to redox regulate 
nitrite reductase activity 
during hypoxia  
(Crawford, et al., 2006  
Rat  Hypertension  Hb-NO complex  Acute: sodium nitrite (1, 
3, 10 mg/kg) by oral 
gavage. Chronic: sodium 
nitrite supplemented in 
drinking water (100 mg/L 
or 1000 mg/L)  
Orally administered 
nitrite is detectable in the 
circulation as HbNO. 
Nitrite treatment 
attenuates L-NAME 
induced hypertension in 
a dose-dependent 
manner  
(Tsuchiya, et al., 2005)  
Ovine  Assessed inhaled sodium 
nitrite by aerosol in 
hypoxia-induced 
pulmonary hypertension 
in newborn lambs  
Hb and iron-nitrosyl-Hb  Inhaled nebulized sodium 
nitrite 15 mg/min for 20 
minutes  
Pulmonary vasodilatation 
was elicited by aerosol 
nitrite. This was deoxyHb, 
pH dependent and 
associated with increased 
(Hunter, et al., 2004)  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
63 
 
blood levels of iron-
nitrosyl-Hb  
Rat  Assessed the role of NO-
modified Hb in isolated 
rat thoracic aortas  
DeoxyHb  In vitro sodium nitrite  Sodium nitrite was 
associated with reduction 
of nitrite to NO by 
deoxyHb during hypoxic 
conditions  
(Cosby, et al., 2003)  
Swine  In vitro and ex vivo 
assessment of nitrite in 
isolated perfused and 
ventilated pig lungs  
-  Lungs: perfusion of buffer 
containing 0.1 and 1 
mmol/L nitrite anions 
from sodium nitrite  
Nitrite anions at 
physiological 
concentrations act as a 
vasodilator  
(Demoncheaux, et al., 
2002)  
Rat  Assessed effect of pH on 
nitrite-induced 
vasorelaxation in rat 
aorta  
-  Cumulative addition of 
sodium nitrite 0.5 to 
1000μM  
Nitrite induced 
vasorelaxation, which 
was enhanced under 
acidic conditions and 
nitrite-derived NO was 
generated in a pH-
dependent manner. 
Vasoactivity of nitrite was 
greatly reduced by 
inhibition of sGC  
(Modin, et al., 2001)  
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Table 2 
 Condition/model  Nitrite reductase  Dose/ route/timing 
administration of nitrite  
Results  Reference  
Hypertension model. Grade 1 
hypertensive patients  
XOR derived from RBC's  Dietary nitrate via 250 ml 
beetroot juice containing 
~3.5 mmol nitrate  
Hypertensive patients 
showed a dose-dependent 
effect of plasma nitrite with 
decrease in BP and was 
associated with increased 
XOR activity. The study 
showed that this effect was 
associated with increase in 
erythrocytic XOR expression 
but not in the blood vessel 
wall  
(Ghosh, et al., 2013)  
CHF patients (NYHA class II-
III) compared to healthy 
volunteers. Hemodynamic 
assessment of unstressed 
forearm venous volume and 
FBF  
-  30 minutes intravenous 
infusion of sodium nitrite 
(0.31 - 7.8 μmol/min) in the 
forearm brachial artery  
FBF increased markedly in 
CHF patients when 
compared to normal 
subjects. Unstressed forearm 
venous volume increased in 
both CHF and normal 
subjects, with CHF being 
being hyporesponsive when 
compared to healthy 
subjects. CHF patients 
showed accelerated 
transvascular clearance of 
nitrite suggesting increased 
conversion to NO in these 
subjects  
(Maher, et al., 2013)  
Healthy subjects  -  Dietary nitrate via 200g 
beetroot bread containing 
100g beetroot (1.1 mmol 
nitrate)  
Beetroot bread increased 
vasodilatation and decreased 
DBP  
(Hobbs, et al., 2013)  
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Healthy subjects. Assessment 
of inorganic nitrate on 
endothelial function by FMD 
and BP  
-  Potassium nitrate oral 
capsules 8 mmol  
Inorganic nitrate 
supplementation had no 
effect on endothelial 
function despite increases in 
plasma nitrite levels. 
However, inorganic nitrate 
decreased SBP and aortic 
pulse wave velocity, but had 
no effect on DBP  
(Bahra, et al., 2012)  
Healthy subjects  -  Intravenous infusion of 
sodium nitrite for 48 hours 
from 4.2μg/kg/hour to 
533.8μg/kg/hour  
Nitrite induced a decrease in 
MAP in healthy subjects. The 
maximum tolerated dose of 
nitrite was 267μg/kg/hour 
with toxicity occuring at 
446μg/kg/hour. Concluded 
that nitrite was safe to infuse 
for a prolonged period given 
the correct dose  
(Pluta, et al., 2011)  
Healthy subjects. Assessment 
of dietary nitrate and 
supplementation on BP, and 
sex differences in response 
to nitrate  
-  Supplementation with 
potassium nitrate (capsules - 
4 to 24 mmol) or beetroot 
juice 250 ml containing 5.5 
mmol nitrate  
Nitrate supplementation or 
beetroot juice caused an 
increase in plasma nitrite and 
cGMP levels, and was 
associated with decreased 
BP in healthy subjects. Sex 
difference in sensivitity to 
nitrate was dependent on 
baseline plasma nitrite 
concentration and BP, 
whereby males had lower 
baseline nitrite levels and 
higher BP than females. 
Following nitrate 
supplementation males had 
significantly greater 
reduction in BP than the 
females, thus suggesting 
(Kapil, et al., 2010a)  
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differences in nitrate 
conversion to nitrite 
between the two sexes  
Healthy subjects. Assessed 
acute and chronic 
supplementation of nitrate 
on BP and exercise  
-  Dietary nitrate via beetroot 
juice 500 ml (5.2 mmol 
nitrate)/day for 15 days  
Nitrate supplementation 
elevated plasma nitrite 
concentrations both short 
term (2.5 hours) and long 
term (15 days). Increased 
plasma nitrite concentration 
was associated with 
decreased BP and the O2 cost 
of moderate intensity 
exercise  
(Vanhatalo, et al., 2010)  
Healthy subjects. Effect of 
nitrate from Japanese diet on 
BP  
-  Dietary nitrate provided via 
Japanese traditional diet. 
Estimated nitrate intake 18.8 
mg/kg/day  
Consumption of Japanese 
traditional diet over a period 
of ten days increased plasma 
and salivary levels of both 
nitrate and nitrite. Japanese 
traditional diet was 
associated with a decrease in 
BP in healthy normotensive 
subjects  
(Sobko, et al., 2010)  
Healthy subjects. Effect of 
low-dose nitrite on hypoxic 
pulmonary vasodilatation  
-  Sodium nitrite infusion into 
brachial artery 1 μmol/min 
for 30 min  
During hypoxia sodium 
nitrite increased FBF and 
reduced pulmonary arterial 
pressure. No effects were 
observed during normoxia  
(Ingram, et al., 2010)  
Investigated the effects of 
sodium nitrite on FBF in 
patients with sickle cell 
disease. Compared to 
healthy controls (Cosby et 
-  Intravenous infusion of 
sodium nitrite (brachial 
artery: 0.4-40 μmol/min)  
Nitrite infusion increased 
plasma nitrite in a dose-
dependent manner which 
was associated with an 
increase in FBF in both 
(Mack, et al., 2008)  
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al., 2003)  healthy controls (Cosby et 
al., 2003) and patients with 
sickle cell disease. However, 
the response/sensitivity to 
nitrite was reduced in 
patients with sickle cell 
disease  
Healthy subjects. Assessed 
effect of dietary nitrate on 
BP  
 Dietary nitrate via beetroot 
juice 500 ml (nitrate content 
≈45.0 mmol/L)  
Beetroot juice caused an 
increase in plasma nitrite 
levels and decrease in BP. 
This effect was abolished by 
the interruption of 
enterosalivary reduction of 
nitrate to nitrite via spitting. 
The study demonstrated that 
the conversion of nitrate to 
nitrite is essential for 
vasoactivity  
(Webb, et al., 2008b)  
Assessment of FBF and 
forearm venous volume 
during normoxia and hypoxia 
in healthy subjects  
-  Brachial artery infusion of 
sodium nitrite (40 nmol/min 
to 7.84 μmol/min)  
Nitrite was a potent 
venodilator during normoxic 
and hypoxic conditions. 
Whilst nitrite had a modest 
vasodilatory effect in the 
resistance vessels during 
normoxia, the effect was 
potent during hypoxia  
(Maher, et al., 2008)  
Assessed the physiological 
and pharmacological effects 
of sodium nitrite on 
vasodilatory responses  
XOR and deoxyHb  0, 7, 14, 28, 55 and 110 
μg/kg/min 5 mins each dose  
Sodium nitrite was a potent 
vasodilator at near-
physiological concentrations. 
Nitrite was reduced to NO by 
intravascular reactions with 
deoxyHb. In contrast, XOR 
inhibition did not attenuate 
the nitrite-induced 
vasodilatation  
(Dejam, et al., 2007)  
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BP in healthy subjects  -  3 day dietary 
supplementation with 
sodium nitrate (0.1 
mmol/kg/day)  
Short term dietary nitrate 
supplementation increased 
plasma nitrite levels and 
reduced DBP and MAP, but 
did not affect SBP in healthy 
subjects  
(Larsen, et al., 2006)  
Subjects with endothelial 
dysfunction compared to 
healthy subjects  
-  Endogenous plasma nitrite  Subjects with endothelial 
dysfunction displayed lower 
levels of plasma nitrite and 
lower FMD levels than 
healthy subjects  
(Kleinbongard, et al., 2003)  
Assessed the vasodilatory 
properties and bioactivation 
of nitrite in forearm (via FBF) 
before and during exercise  
DeoxyHb  Infusion of sodium nitrite 
0.36 and 36μmol/min before 
and during exercise  
Sodium nitrite induced 
vasodilatation in humans and 
was associated with 
reduction of nitrite to NO by 
deoxyHb during hypoxic 
conditions  
(Cosby, et al., 2003)  
Assessed whether changes in 
NOS concentrations are 
reliable marker for NO 
production and whether 
physiological 
concencentration of nitrite is 
vasoactive  
eNOS  Intra-arterial infusion of 
sodium nitrite 0.01-
36μmol/min  
eNOS stimulation with ACh 
dose-dependently increased 
venous nitrite levels and this 
effect was associated by an 
increase in FBF. Intra-arterial 
infusion of nitrite had no 
effect on FBF  
(Lauer, et al., 2001)  
 
